WHSC1L1 Antibody

What is WHSC1L1 and why is it significant in cancer research?

WHSC1L1 (also known as NSD3) is a histone methyltransferase that plays a fundamental role in chromatin organization. It has been identified as a significant oncogene, with expression levels significantly elevated in various human cancers including bladder carcinoma, lung cancer, and liver cancer . Research has demonstrated that WHSC1L1 knockdown can suppress proliferation of cancer cell lines and induce cell cycle arrest at the G2/M phase, making it a promising target for cancer therapeutics . Recent analyses have ranked WHSC1L1 as a top driver oncogene that is also potentially druggable, highlighting its significance in oncology research .

What applications are WHSC1L1 antibodies validated for?

WHSC1L1 antibodies have been validated for numerous research applications as demonstrated in the following data:

How do I select the appropriate WHSC1L1 antibody isoform for my experiments?

WHSC1L1 exists in multiple isoforms, with the short isoform often expressed at higher levels than the long isoform in cancer cell lines and primary breast cancers . When selecting an antibody, consider:

• The specific isoform of interest (short: 68-72 kDa vs. long: 160-170 kDa)

• The experimental application (some antibodies perform better in specific applications)

• Species reactivity (human, mouse, rat compatibility)

• Antibody class (monoclonal vs. polyclonal) based on your experimental needs

For detecting both isoforms simultaneously, select antibodies targeting conserved epitopes. For isoform-specific detection, choose antibodies recognizing unique regions. TCGA data confirms that WH-short is expressed at higher levels than WH-long in primary breast cancers, which may influence your experimental design .

How can WHSC1L1 antibodies be used to investigate histone methylation patterns?

WHSC1L1 functions as a histone methyltransferase that primarily catalyzes H3K36 dimethylation (H3K36me2) . For investigating histone methylation patterns:

• Use ChIP assays with WHSC1L1 antibodies to determine genomic binding sites

• Combine with H3K36me2-specific antibodies in sequential ChIP (re-ChIP) experiments to confirm co-localization

• Perform WHSC1L1 knockdown studies followed by ChIP-seq for H3K36me2 to determine causality

Experimental evidence shows that WHSC1L1 and H3K36me2 are enriched in the gene bodies of cell cycle-related genes, suggesting a mechanism for how WHSC1L1 drives cell proliferation . When designing such experiments, consider using controls for antibody specificity and include positive controls for known WHSC1L1 target genes.

What is the relationship between WHSC1L1 expression and estrogen receptor signaling in breast cancer?

WHSC1L1 has been implicated in estrogen receptor signaling through several mechanisms:

• WHSC1L1 knockdown reduces ERα protein levels in cell models like SUM-44

• The 8p11 amplicon containing WHSC1L1 most often occurs in luminal B breast cancers, which are typically ER-positive

• WHSC1L1 appears to drive over-expression of the ESR1 gene and ERα protein, resulting in ERα that is transcriptionally active in an estrogen-independent manner

To investigate this relationship, researchers can:

• Use WHSC1L1 antibodies in IHC to correlate expression with ER status in patient samples

• Perform co-immunoprecipitation experiments to identify potential physical interactions between WHSC1L1 and ER pathway components

• Conduct ChIP-seq analysis to determine if WHSC1L1 directly binds to ESR1 regulatory regions

How can multi-omics approaches incorporate WHSC1L1 antibody-based data?

Integrating WHSC1L1 antibody-based data into multi-omics studies can provide comprehensive insights into its role in cancer:

• Combine ChIP-seq (using WHSC1L1 antibodies) with RNA-seq after WHSC1L1 knockdown to correlate binding with gene expression changes

• Integrate WHSC1L1 IHC data from tissue microarrays with genomic data to associate protein expression with genetic alterations

• Correlate WHSC1L1 protein levels (detected via antibodies) with histone modification profiles and DNA methylation patterns

Studies have shown that expression profile analysis using microarrays revealed WHSC1L1 affects the expression of genes including CCNG1 and NEK7, which play crucial roles in cell cycle progression at mitosis . This approach can identify direct and indirect targets of WHSC1L1 regulatory activity.

What are the optimal conditions for WHSC1L1 antibody use in immunohistochemistry?

For optimal IHC results with WHSC1L1 antibodies, consider these evidence-based recommendations:

• Antigen retrieval: Use TE buffer pH 9.0 (alternatively, citrate buffer pH 6.0)

• Antibody dilution: 1:400-1:1600 for commercial polyclonal antibodies

• Detection system: Select based on tissue type and expression level

• Positive controls: Human lung squamous cell carcinoma tissue is recommended

When analyzing WHSC1L1 expression in patient samples, researchers have found significant overexpression in SCCHN, associated with poor grade and heavy smoking history . Always perform optimization on control tissues and include both positive and negative controls in each experiment.

What strategies can resolve specificity issues with WHSC1L1 antibodies?

To ensure WHSC1L1 antibody specificity:

• Validate with WHSC1L1 knockdown/knockout controls to confirm signal reduction

• Use different antibody clones targeting distinct epitopes to confirm consistent localization

• Perform peptide competition assays to confirm epitope specificity

• Include western blot validation to confirm detection of the correct molecular weight species (160-170 kDa for long isoform, 68-72 kDa for short isoform)

Research has shown that the short isoform of WHSC1L1 is often expressed at higher levels than the long isoform in cancer cell lines , which may complicate interpretation of antibody signals. Recognizing which isoform(s) your antibody detects is critical for accurate data interpretation.

What are the recommended procedures for ChIP experiments using WHSC1L1 antibodies?

For successful ChIP experiments with WHSC1L1 antibodies:

• Crosslinking: Standard 1% formaldehyde for 10 minutes at room temperature

• Chromatin fragmentation: Aim for 200-500 bp fragments

• Antibody amount: 0.5-4.0 μg per immunoprecipitation

• Controls: Include IgG control and positive control for known WHSC1L1 targets

ChIP analysis has demonstrated that WHSC1L1 and H3K36me2 are enriched in the gene bodies of cell cycle-related genes . When designing primers for ChIP-qPCR validation, focus on gene body regions rather than promoters, as WHSC1L1 tends to bind within transcribed regions.

How can I resolve inconsistent WHSC1L1 antibody performance across different cell lines?

Inconsistent antibody performance may result from:

• Varying WHSC1L1 expression levels: Some cancer types show significantly elevated expression compared to others

• Isoform differences: The short isoform is often expressed at higher levels than the long isoform

• Post-translational modifications affecting epitope accessibility

Troubleshooting approaches:

• Test multiple antibody concentrations for each cell line

• Optimize lysis conditions to ensure complete protein extraction

• Consider cell type-specific fixation protocols for IF/IHC

• Use positive control cell lines with known WHSC1L1 expression (HeLa, HEK-293 for WB; MCF-7 for IF)

What are common pitfalls when measuring WHSC1L1 expression in patient samples?

When analyzing patient samples:

• Tumor heterogeneity may lead to variable WHSC1L1 expression within the same specimen

• Fixation artifacts can affect epitope recognition, particularly in FFPE samples

• Background staining may complicate interpretation, especially in tissues with endogenous peroxidase activity

To address these challenges:

• Use tissue microarrays with multiple cores per patient to account for heterogeneity

• Optimize antigen retrieval protocols (TE buffer pH 9.0 recommended)

• Include normal tissue controls to establish baseline expression

• Consider dual staining with cell type-specific markers to identify WHSC1L1-expressing cell populations

Studies using immunohistochemistry on tissue microarrays have successfully demonstrated WHSC1L1 overexpression in SCCHN patients and its association with clinical parameters .

How can conflicting results between protein and mRNA expression of WHSC1L1 be reconciled?

Discrepancies between WHSC1L1 protein and mRNA levels may arise from:

• Post-transcriptional regulation mechanisms

• Protein stability differences between contexts

• Technical limitations in detection methods

• Differential isoform expression not captured by some assays

To reconcile such discrepancies:

• Perform parallel analysis of mRNA (qPCR/RNA-seq) and protein (WB/IHC)

• Use isoform-specific primers and antibodies to distinguish variants

• Consider polysome profiling to assess translational efficiency

• Examine protein stability through cycloheximide chase experiments

Research has shown that while WHSC1L1 transcript levels are significantly elevated in various cancers, protein expression patterns may show additional complexity .

How are WHSC1L1 antibodies being used to develop potential cancer therapeutics?

WHSC1L1 expression is significantly low in various normal tissues including vital organs, making it a promising candidate for targeted cancer therapy . Current research approaches include:

• Using antibodies to validate WHSC1L1 as a therapeutic target in preclinical models

• Developing screening assays for small molecule inhibitors of WHSC1L1 methyltransferase activity

• Investigating synthetic lethality approaches by identifying genes that, when inhibited alongside WHSC1L1, cause selective cancer cell death

• Exploring the potential of antibody-drug conjugates targeting cell-surface proteins regulated by WHSC1L1

Research has demonstrated that WHSC1L1-specific siRNAs significantly knock down its expression and suppress proliferation of bladder and lung cancer cell lines, providing proof-of-concept for therapeutic targeting .

What emerging technologies are enhancing WHSC1L1 antibody applications in research?

Novel technologies extending WHSC1L1 antibody applications include:

• CUT&RUN/CUT&Tag methods providing higher resolution chromatin binding profiles than traditional ChIP

• Single-cell antibody-based techniques to examine WHSC1L1 expression heterogeneity

• Proximity ligation assays to study WHSC1L1 protein-protein interactions in situ

• CRISPR-based screening combined with WHSC1L1 antibody readouts to identify functional pathways

These approaches are enabling researchers to better understand the context-specific functions of WHSC1L1 in different cancer types and cellular environments.

How is the WHSC1L1 interactome being mapped using antibody-based approaches?

Researchers are mapping the WHSC1L1 interactome through:

• Co-immunoprecipitation followed by mass spectrometry to identify protein binding partners

• Proximity-dependent biotin labeling (BioID/TurboID) coupled with WHSC1L1 antibody validation

• ChIP-seq with sequential immunoprecipitation to identify co-binding factors at genomic loci

• Antibody-based protein microarrays to screen for novel interactions

These studies are revealing how WHSC1L1 participates in larger protein complexes that regulate chromatin structure and gene expression. Understanding these interactions may uncover new therapeutic vulnerabilities in cancers with WHSC1L1 overexpression.